SCYNEXIS wins BARDA contract worth up to $214 million for SCY-247 development
SCYX•SCYNEXIS won a BARDA contract worth up to $214 million to fund SCY-247 development. The $18.5 million base period is intended to advance oral and IV versions into a Phase 2 trial for invasive candidiasis.
1. Contract details
The contract’s base period provides $18.5 million to move oral and IV SCY-247 into a Phase 2 trial for invasive candidiasis. It includes an option to support a second indication focused on prevention in high-risk patients, and its term can extend up to 10 years.
